The Global Centre for Risk and Innovation (GCRI)
Health and biotechnology research moves from bench to animal to human to population, and each step has its own ethics, safety and evidence rules. One Health links that chain to animals and environments, where many emerging pathogens begin. This lab studies how biomedical and biotech innovation is designed, contained, evaluated and translated, and what ethics committees, biosafety committees and regulators need before they let it move on.
GCRI · Established · service level R0
Translational research is the movement of biomedical findings from laboratory to animal studies, human trials and population use. Each step has its own ethics, safety and evidence rules; signal is often lost on the way, and dual-use research and One Health links to animals and environments add oversight needs.
For future of health and bio labs, in GCRI's spatial-intelligence reading, the map opens on true-colour imagery, population density and land cover with true colour from NASA GIBS, framed on World; every other NASA layer, live feed and forecast waits in the layer list.
The interactive map needs JavaScript; the layer list and sources are below.
Layers 3
Environmental exposure, for this page
Keyboard, with the map focused
Hold Ctrl or ⌘ and scroll to zoom
Latest available
NASA GIBS / EOSDIS · ASTER GDEM (METI, NASA) · Blue Marble (NASA) · © OpenStreetMap contributors (ODbL) · Natural Earth
Loading the latest NASA imagery.
Drag to move. Ctrl or ⌘ and scroll, pinch or the buttons to zoom; hover for the values under the pointer; reset returns to the region.
For future of health and bio labs, in GCRI's spatial-intelligence reading, the map opens on true-colour imagery, population density and land cover with true colour from NASA GIBS, framed on World; every other NASA layer, live feed and forecast waits in the layer list.Satellite and model products as NASA publishes them, each with its own date; indicators, not assessments of any place; claim ceiling INTEGRATED.
Layers and dates
The working screen behind this subject: its structure, terms and states. Names are placeholders and values illustrative.
Future of health and biotechnology labs · Field lab coast · Campaign 3
placeholder coastline
| S-01 tide | 95 | 0.2 | Nominal |
| S-04 salinity | 85 | 0.7 | Recalibrate |
| S-07 wave | 90 | 0.1 | Nominal |
Human health, One Health and biotech. The dossier below sets out how the risk develops, what is measured, where the data come from, how it is modelled and who decides.
Results in cells and animals often fail in people because of species differences, small samples, unblinded studies and selective publication. Weak preclinical evidence can send trials forward that expose participants without good reason.
Techniques that enhance, synthesise or edit organisms can serve harm as well as health. Containment, oversight of dual-use research and screening of synthetic DNA orders manage risks that cross laboratory walls.
Pathogens and resistance genes move between animals, people and environments through farming, trade, water and wildlife contact. Research that studies one host alone can miss the pathway that matters.
Trials and datasets underrepresent many populations, regions and conditions. Treatments and diagnostic models built on that evidence can perform worse for groups that were not studied, and the gap is often invisible in pooled results.
Each term as this page uses it. Where a standard-setting body defines the term, the wording follows that body.
| Term | Definition |
|---|---|
| Dual-use research of concern | Life sciences research that could be directly misapplied to threaten health, agriculture, the environment or security. |
| ARRIVE guidelines | Reporting guidelines for research involving animals, listing essential items such as randomisation and blinding. |
| Trial registration | Recording a clinical trial in a public registry before the first participant is enrolled. |
Each indicator carries its unit, its cadence, the kind of source behind it and the evidence label a value would carry. No values are shown: a programme supplies them under its own authority.
| Indicator | Unit | Cadence | Source type | Label |
|---|---|---|---|---|
| Trial registration before enrolment | percent of trials | annual | Trial registries | OFFICIAL |
| Results reported within the required period | percent of completed trials | annual | Registry results sections | OFFICIAL |
| ARRIVE essential items reported | percent of items | per study | Animal study reporting audits | OBSERVED |
| Randomisation and blinding in preclinical studies | percent of studies | annual | Systematic reviews of animal research | ESTIMATED |
| Enrolment relative to the affected population | ratio of enrolled share to affected share, by group | per trial | Trial enrolment data | REPORTED |
| National dual-use research oversight | policy in place, yes or no | annual | Biosafety governance mapping | OFFICIAL |
| Health research funding by disease | national currency at constant prices | annual | Funding trackers | REPORTED |
The topic as a computational graph: named sources feed the methods, an evidence review gates the outputs, and the decisions stay with the authorities that hold them.
Fig. 02Nodes carry their type, two metric rows and a state; connectors show what feeds what; dashed frames name the owners; the timeline is the cadence. Design of the pipeline, not a record of a run.
Named public datasets and institutional records, each with its licence class. Sources by agreement are used only under their terms and never republished.
| Source | What it gives | Licence class |
|---|---|---|
| ClinicalTrials.gov (US National Library of Medicine) | Registered trials, enrolment and results | Public domain |
| WHO International Clinical Trials Registry Platform | Records from primary national registries | Free, WHO terms of use |
| Clinical Trials Information System (European Medicines Agency) | Authorised trials in the EU and their results | Public, EMA terms |
| WHO Global Observatory on Health R&D | Health research funding, trials and products by disease and region | WHO terms, CC BY-NC-SA IGO |
| Europe PMC | Biomedical literature with open full text and links to data | Free access, licence per article |
| Global BioLabs (King's College London and George Mason University) | High-containment laboratories and national biosafety and biosecurity policies | Free access, attribution |
| G-FINDER (Policy Cures Research) | Funding for research on neglected and emerging infectious diseases | Free access, terms of use |
Nexus Labs prepares evidence. The decisions below are taken by the authorities named, under their own rules, and never by the platform.
| Who decides | The question | Evidence this page serves |
|---|---|---|
| Research ethics committees | Whether a study with human participants may begin or continue | Protocol, prior evidence, risks and benefits, consent materials, data monitoring plan |
| Animal welfare bodies | Whether animal use is justified, minimised and refined | Harm-benefit assessment, sample size rationale, alternatives considered under the Three Rs |
| Institutional biosafety committees and national biosecurity authorities | Whether work at a given containment level or with dual-use potential may proceed | Risk assessment, containment, training, oversight and screening arrangements |
| Medicines regulators | Whether a product's evidence supports authorisation for the intended population | Trial results, representation of the intended population, preclinical package |
The One Health approach recognises that human, animal and ecosystem health are interdependent. Many emerging infectious diseases originate in animals, and spillover risk is shaped by land-use change, wildlife trade, livestock systems and climate. Antimicrobial resistance develops wherever antimicrobials are used, in human medicine, agriculture and the environment, and spreads through water, food and travel.
Heat is a direct health hazard, especially for older people, outdoor workers and those with chronic illness, and it interacts with air pollution and power outages. Flooding and drought affect water quality and sanitation, raising the risk of waterborne disease. Health facilities depend on electricity, water, supply chains and staff who can reach work.
Biotechnology brings new tools for diagnosis, vaccines and treatment, and new risks if techniques are misused or containment fails. Biosafety concerns accidental harm; biosecurity concerns deliberate misuse.
Cohort, case-control and time-series designs relating exposures to outcomes. Confounding and reporting gaps limit causal claims.
Linking human, animal and environmental data, including wastewater monitoring. Coverage is uneven and data sharing is often restricted.
Research under biosafety rules and containment levels set by competent authorities. Laboratory results require field confirmation.
Transmission and exposure models using probability and statistics. Models depend on uncertain parameters and behaviour.
No Labs activity involving pathogens, human participants or animals proceeds without approval from the competent ethics and biosafety bodies for that study and site.
The current service level is R0: information and enquiries. An enquiry receives a reference and names the next step; applications, payments, compute allocations and registrations open only when their team, terms and review capacity exist.